Avita Medical (NASDAQ:RCEL) expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025, President and CEO Cary Vance said at the Canaccord 46th Annual Boston Growth Conference.
Vance, who has been CEO for about 10 months after previously serving on the company’s board, described Avita as a hospital-based acute wound care company focused on burn centers, Level 1 trauma centers and certain reconstructive and cosmetic surgery settings. He distinguished the company’s business from chronic wound care, which is often handled in office-based settings.
Revenue growth and financial outlook
Vance cited revenue growth over the past several reported quarters, from $17.6 million to $19.3 million to $21.7 million. He said the company has focused on stabilizing the business and establishing an organic, quarter-over-quarter growth trajectory.
Avita raised its 2025 revenue guidance to $86 million to $89 million, from a prior range of $80 million to $85 million. Vance said the company expects to hold operating expenses and margins relatively consistent as revenue grows, supporting its goal of becoming cash flow breakeven in the fourth quarter.
As of the end of the second quarter, the company had $11 million of cash available, Vance said. He added that Avita’s use of cash has declined and that the company does not expect to need additional operating expense investment to support near-term growth.
Vance said Avita has positioned its commercial organization to grow without adding sales representatives for at least a year and a half or longer, assuming it continues to expand quarter by quarter. While he did not provide a total sales-force headcount, he said representatives generally cover three to four accounts each and are deployed nationwide.
Three-product acute wound portfolio
Avita’s portfolio includes RECELL, Cohealyx and PermeaDerm, which Vance said can be used at different stages of treatment for patients with large burns or traumatic wounds.
- PermeaDerm is used as a biosynthetic dressing or temporizer after a wound is cleaned and excised. Vance said it is transparent, allowing clinicians to protect and assess the wound before determining how to close it.
- Cohealyx is a dermal matrix intended to prepare and vascularize the wound bed before grafting.
- RECELL can be used alone to spray skin cells or alongside split-thickness or meshed skin grafts. The RECELL line includes the manual RECELL product, automated RECELL GO and smaller RECELL GO mini for smaller wounds.
Vance said the three products can be sold into the same hospitals and used by the same physicians, making the portfolio more efficient for the company’s sales force. About 25 U.S. hospitals currently use all three products, he said.
The CEO said RECELL competes largely with traditional skin-grafting approaches. He cited company data showing a 36% reduction in length of stay for patients using RECELL compared with split-thickness skin grafting.
For Cohealyx, Vance said the principal advantage is speed to wound-bed readiness. He said a study showed wound beds could be ready for grafting in as little as five days, compared with up to 20 additional days for competing dermal matrices. For PermeaDerm, he said the product competes with allograft, or cadaver skin, and is designed to offer transparency, easier handling and lower cost.
Reimbursement and market penetration
Vance said reimbursement uncertainty over the past 12 to 18 months affected some clinicians’ willingness to use or trial RECELL. In the first quarter of 2025, he said the Centers for Medicare & Medicaid Services directed Medicare Administrative Contractors to address reimbursement, resulting in a slow publication process that created confusion among surgeons.
According to Vance, the contractors have since published their policies and are paying claims. He said a simplified national reimbursement code is scheduled to begin on Jan. 1, 2027, and Avita does not expect disruption from the transition.
Despite having been in the market for some time, Vance said Avita remains underpenetrated. The company estimates it has reached about 15% penetration even in its core market of larger wounds and burn centers, while penetration in trauma and smaller wounds remains limited.
Looking ahead, Vance said the company’s next major objective beyond cash flow breakeven is continued growth. With margins in the “80-something percent” range and operating expenses held steady, he said revenue expansion should move the business from breakeven toward profitability over time.
About Avita Medical (NASDAQ:RCEL)
Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient’s own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures.
Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S.
